Can You Reach EASI Targets Faster? – AD Case with Prof. Naiem Issa

0 SAR
Checkout

Overview

In this video, Prof. Naiem Issa presents the clinical efficacy data of lebrikizumab (LEBRI) in atopic dermatitis as demonstrated in the ADvocate 1 and ADvocate 2 studies at Week 16, highlighting significant improvements across key endpoints including EASI, IGA 0/1, and Pruritus NRS. Linking this evidence to real‑world clinical practice by showcasing a patient case with visible and meaningful improvement as early as Week 2, reinforcing the “Start Strong” concept to support rapid progression toward long‑term treatment targets.


This Class for

  • Physician
  • Resident / Fellow

What I will learn?

    • To highlight the “Start Strong” treatment concept with lebrikizumab in atopic dermatitis (ADvocate 1 & 2)
    • To review key efficacy endpoints: EASI‑75, EASI‑90, IGA 0/1, and Pruritus NRS at 16 weeks.
    • To translate rapid clinical response into practical insights for daily dermatology practice.

     

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
    Please go to PDF Material for prescribing information.

    PP-LK-SA-0263


Related Classes